Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Amiodarone induced pulmonary toxicity].

P Alter1, W Grimm, B Maisch

  • 1Zentrum für Innere Medizin - Kardiologie, Philipps-Universität Marburg/Lahn, Germany. alter@mailer.uni-marburg.de

Pneumologie (Stuttgart, Germany)
|January 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and outcomes of patients hospitalized for infection with Influenza A, SARS-CoV-2 or respiratory syncytial virus in the season 2023/2024 in a large German primary care centre.

European journal of medical research·2024
Same author

Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.

Respiratory research·2024
Same author

Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET.

Respiratory research·2024
Same author

Characteristics and outcomes of patients hospitalized for infection with influenza, SARS-CoV-2 or respiratory syncytial virus in the season 2022/2023 in a large German primary care centre.

European journal of medical research·2023
Same author

Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET.

Scientific reports·2020
Same author

The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET.

Respiratory research·2020

Amiodarone, a class III antiarrhythmic drug, can cause rare but severe pulmonary toxicity in dilated cardiomyopathy patients. Early drug discontinuation can reverse lung damage, highlighting the need for vigilant monitoring.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Amiodarone is a widely used Class III antiarrhythmic for supraventricular and ventricular tachycardia.
  • Pulmonary toxicity, potentially leading to lung fibrosis, is a rare but serious side effect of amiodarone.
  • Limited data exists on amiodarone's pulmonary toxicity specifically in dilated cardiomyopathy (DCM) patients.

Observation:

  • Two cases of dilated cardiomyopathy patients developed pulmonary toxicity after 6 weeks and 8 months of amiodarone treatment.
  • Pulmonary toxicity was confirmed by excluding other causes via bronchoscopy, bronchoalveolar lavage, and biopsy.
  • Pulmonary function improved significantly within weeks after discontinuing amiodarone.

Findings:

  • Amiodarone-induced pulmonary toxicity can lead to respiratory insufficiency in DCM patients.

Related Experiment Videos

  • Pulmonary toxicity is a rare, potentially fatal adverse effect of amiodarone therapy.
  • Early detection and discontinuation of amiodarone are crucial for reversing pulmonary changes.

    • Implications:

    • Heart failure symptoms in DCM patients may mask early signs of pulmonary amiodarone toxicity.
    • Periodic monitoring of pulmonary function, including bronchoscopy, bronchoalveolar lavage, biopsy, and diffusion capacity, is recommended during amiodarone therapy for DCM.
    • This underscores the importance of a multidisciplinary approach to managing patients on long-term amiodarone therapy.